Shenzhen, China — November 2025
Hemogen Therapeutic announced that it has been awarded the “Outstanding Clinical Achievement in Cell Therapy” at the 14th Cell Biology Industry Conference, held from November 13–15, 2025. The recognition highlights Hemogen’s significant progress in clinical translation, technology innovation, and global deployment of cell and gene therapies.
Dr. Chao Liu, Chief Executive Officer of Hemogen Therapeutic, was invited to deliver a keynote speech at the conference, sharing the company’s advancements in hematopoietic stem cell gene therapy and its international strategy.
Remarkable Clinical Outcomes and Accelerated Global Expansion
Hemogen’s lead product, HGI-001 Injection (Hemocel), developed for transfusion-dependent β-thalassemia, has demonstrated strong and durable efficacy. The first treated patient has now surpassed four years of follow-up, with sustained transfusion independence and an excellent safety profile.
In April 2025, Hemo-cel received clinical trial approval from the Thailand Food and Drug Administration (TFDA), becoming the first China-developed hematopoietic stem cell gene therapy product to enter the clinical stage overseas. Hemogen subsequently established its first overseas manufacturing line in Thailand, marking a major milestone in the global deployment of Chinese gene therapy products.
The company has also submitted a IND to the Saudi Food and Drug Authority (SFDA), which is currently under technical review and expected to be approved within the year. In parallel, Hemogen is advancing strategic collaborations in Jordan and Bahrain, extending its presence across the Middle East.
Given the high prevalence of hemoglobinopathies and limited local treatment capacity in many Belt and Road countries, Hemogen is pioneering an innovative collaboration framework based on “License-out and/or Integrated Solutions (Technology Transfer)”.
• For mature pipelines such as HGI-001 and HGI-002, Hemogen provides regional licensing and/or full technology transfer to partners in the Middle East and Southeast Asia, enabling shared clinical data packages and accelerated local regulatory approval.
• For regions with weaker technical infrastructure, Hemogen offers a comprehensive “Celaxi-23 automated device + ready-to-use reagent kits + manufacture training” turnkey solution, enabling rapid deployment of local cell manufacturing capability and lowering technical barriers.
By integrating upstream and downstream resources and promoting the adoption of its proprietary equipment and consumables, Hemogen is forming a sustainable international model of “overseas licensing/technology transfer + ecosystem-based value realization.” This approach supports the development of localized gene therapy ecosystems and delivers affordable curative solutions for regions heavily affected by genetic blood disorders.
Technology Innovation Leading the Next Wave of Gene Therapy
Hemogen Therapeutic has established a robust technical platform centered on hematopoietic stem cell gene therapy, combining proprietary lentiviral transduction technologies with advanced gene-editing capabilities to create an efficient end-to-end development and manufacturing ecosystem.
The company’s Celaxi-23 automated manufacturing platform enables full-process automation—from stem cell collection, transduction, and expansion to final product release—significantly improving manufacturing consistency, reducing manual variability, and increasing throughput.
This system is complemented by Hemogen’s stem cell functional enhancement technologies, which improve expansion efficiency and product potency, supporting scalable, cost-effective, and globally deployable gene therapy manufacturing.
Leveraging its comprehensive quality systems and strong regulatory compliance foundation, Hemogen has been recognized as a National High-Tech Enterprise and a Shenzhen Specialized and Innovative Enterprise, and has been ranked among China’s most promising innovators in the life sciences sector. These achievements underscore Hemogen’s leadership in advancing the industrialization of gene therapy in China.
From China to the World
Receiving the “Outstanding Clinical Achievement in Cell Therapy” award affirms Hemogen Therapeutic’s significant contributions in clinical advancement, technological innovation, and global deployment of gene therapy solutions. Looking ahead, Hemogen will continue to drive progress through a dual-engine strategy of technological breakthroughs and model innovation, deepening collaborations with global partners and accelerating the international clinical adoption of hematopoietic stem cell gene therapies.
Guided by the mission of Gene Technology for the Benefit of Humanity and the vision of achieving a world with no thalassemia, Hemogen Therapeutic is advancing from China to the world—bringing innovative, accessible, and life-changing therapies to patients and families across the globe.
